▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 29, 2024

Bio

Samsung Bioepis’ first biosimilar logs fast sales growth in Europe

  • PUBLISHED :February 01, 2017 - 17:18
  • UPDATED :February 01, 2017 - 17:18
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print

[THE INVESTOR] Samsung Bioepis, a joint venture between Biogen and  Samsung BioLogics, is expanding its foothold in Europe as the sales of its first biosimilar are growing at a fast clip.

The sales of Benepali, the biosimilar referencing Enbrel, in the European market stood at US$100.6 million last year, according to a regulatory filing of Biogen on Jan. 31.

Samsung Bioepis has awarded Biogen the rights to sell the drug in Europe. 


In the fourth quarter only, the sale of Benepali shot up to US$527 million, surpassing the cumulative sales of US$47.9 million in the first nine months.

Benepali is the first biosimilar version of Amgen’s multibillion dollar anti-inflammatory Enbrel that has been approved in the EU.

Since it won approval in January last year, it has been launched in 28 EU countries as well as Norway, Iceland and Liechtenstein.

On the back of strong sales, Benepali also seeks to tap the Central and Eastern European markets.

On Jan. 23, Biogen singed a distribution agreement with Swiss-based Ewopharma to sell Benepali and another Samsung Bioepis’ biosimilar Flixabi in six countries, Romania, Bulgaria, Croatia, Estonia, Latvia and Lithuania.

By Park Han-na (hnpark@heraldcorp.com)

EDITOR'S PICKS